Therapy including imatinib. Medical search. Frequent questions

Patients receive oral imatinib mesylate twice daily on days 1-28. (knowcancer.com)
One of the best-characterized forms of HES is the one associated with FIP1L1-PDGFRA gene rearrangement, which was recently demonstrated as responsive to treatment with the small molecule kinase inhibitor drug, imatinib mesylate. (wjgnet.com)
According to IQVIA, US sales of Imatinib Mesylate Tablets were approximately $831 million in the 12 months ending August 2018. (hikma.com)
Imatinib mesylate is often associated with edema and occasionally serious fluid retention. (hikma.com)
65 years) or those taking higher doses of imatinib mesylate. (hikma.com)
Severe superficial edema was reported in 1.5% of newly diagnosed CML patients taking imatinib mesylate, and in 2%-6% of other adult CML patients taking imatinib mesylate. (hikma.com)
In addition, other severe fluid retention (e.g., pleural effusion, pericardial effusion, pulmonary edema, and ascites) reactions were reported in 1.3% of newly diagnosed CML patients taking imatinib mesylate, and in 2%-6% of other adult CML patients taking imatinib mesylate. (hikma.com)
In a randomized trial in patients with newly diagnosed Ph+ CML in chronic phase comparing imatinib mesylate and nilotinib, severe (Grade 3 or 4) fluid retention occurred in 2.5% of patients receiving imatinib mesylate and in 3.9% of patients receiving nilotinib 300 mg twice daily. (hikma.com)
Effusions (including pleural effusion, pericardial effusion, ascites) or pulmonary edema were observed in 2.1% (none were Grade 3 or 4) of patients in the imatinib mesylate arm and 2.2% (0.7% Grade 3 or 4) of patients in the nilotinib 300 mg twice daily arm. (hikma.com)
Some drugs, such as rituximab (Rituxan), mycophenolate mofetil (CellCept), and imatinib mesylate (Gleevac), used to treat certain autoimmune diseases and cancers may play a role in treating scleroderma. (mountsinai.org)
Imatinib mesylate is a novel anti-tumor agent useful in the clinical management of chronic myelogenous leukemia and gastrointestinal stromal tumors with minimal toxicity relative to other forms of cancer therapy. (oldcitypublishing.com)
The US Food and Drug Administration (FDA) recently approved sunitinib malate (Sutent) capsules for two types of cancer: advanced renal cell carcinoma and malignant gastrointestinal stromal tumor (GIST), after disease progression on or intolerance to the frontline drug imatinib mesylate (Gleevec). (cancernetwork.com)
The CHMP also backed approval of Bristol-Myers Squibb's Sprycel (dasatinib) for the treatment of chronic myeloid leukaemia in patients with resistance or intolerance to prior therapy including Novartis' Glivec (imatinib mesylate), and acute lymphoblastic leukaemia in patients with resistance or intolerance to prior therapy. (pharmatimes.com)
Tasigna demonstrated that significantly fewer patients progressed to more advanced stages of the disease than the standard of care Gleevec (imatinib mesylate) tablets* at 12 months. (salesandmarketingnetwork.com)
Imatinib mesylate (IM), a potent inhibitor of the BCR/ABL tyrosine kinase, has become standard first-line therapy for patients with chronic myeloid leukemia (CML), but the frequency of resistance increases in advancing stages of disease. (lu.se)
Tenax Therapeutics is developing novel dosing and a unique formulation of imatinib mesylate, a kinase inhibitor that has received FDA's orphan designation (March 2020) for the treatment of pulmonary arterial hypertension (PAH). (biospace.com)
Imatinib mesylate, a small-molecule inhibitor of the KIT tyrosine kinase, provides a rapid but not durable clinical response in KIT-mutant melanoma. (elsevierpure.com)
Herein, we designed clinical trial of co-administrating imatinib mesylate and pembrolizumab (anti-PD-1 antibody) to evaluate its safety and efficacy.Methods and analysis:This is an open-label, single-arm, phase I/II clinical trial involving Japanese patients with metastatic KIT-mutant melanoma that are refractory to standard therapy including anti-PD-1 therapy. (elsevierpure.com)
Phase I study is a dose-escalation study comprising two dose levels of imatinib mesylate (200 and 400 mg/day, respectively) with fixed dose of pembrolizumab (200 mg every 3 weeks) to evaluate safety and tolerability and determine recommended phase II dose. (elsevierpure.com)
The primary endpoint of the phase II study is the objective response rate after 4 cycles (3 weeks/cycle) of pembrolizumab and imatinib mesylate at the dose determined in phase I, based on RECIST version 1.1. (elsevierpure.com)

Imatinib, sold under the brand names Gleevec and Glivec (both marketed worldwide by Novartis) among others, is an oral targeted therapy medication used to treat cancer. (wikipedia.org)
At the time of diagnosis, the patient was treated with imatinib (Gleevec, Novartis) therapy, which was continued for 3 years. (ophthalmologytimes.com)
We describe areas where major inroads were initially achieved by targeting angiogenesis and by unraveling pathways in the heterogeneous tumors of mesenchymal origin-spurred by the identification of c-Kit-activating mutations in GIST and the regressions that ensued when tumors harboring these mutations were exposed to the tyrosine kinase inhibitor imatinib (Gleevec). (cancernetwork.com)
Tasigna also showed a statistically significant improvement over Gleevec in every other measure of efficacy in the trial, including major molecular response (MMR) and complete cytogenetic response (CCyR) at 12 months(1). (salesandmarketingnetwork.com)
Recently presented data showed that Tasigna surpassed Gleevec in every measure of treatment efficacy designated in the study including prevention of disease progression at 12 months," said David Epstein, CEO of the Novartis Pharmaceuticals Division. (salesandmarketingnetwork.com)
Tasigna has been approved in more than 80 countries for the treatment of chronic phase and accelerated phase Ph+ CML in adult patients resistant or intolerant to at least one prior therapy, including Gleevec. (salesandmarketingnetwork.com)
Currently, imatinib, or Gleevec®, is the approved initial therapy for CML, which has increased the five-year survival rate for the disease from 50 percent to 90 percent, said Kantarjian. (mdanderson.org)
Before we get into where things will head in the future, I want to go back to Gleevec ( imatinib ). (medscape.com)

Cancer Research UK carried out vital lab research laying the foundations for today's targeted therapies, including trastuzumab (Herceptin), imatinib (Glivec), vemurafenib (Zelboraf), vismodegib (Erivedge) and more. (cancerresearchuk.org)
Glivec (imatinib) Product Information. (medscape.org)
https://www.ema.europa.eu/documents/product-information/glivec-epar-product-information_en.pdf. (medscape.org)
Known as Glivec (imatinib) outside the US, Canada and Israel. (salesandmarketingnetwork.com)
Tasigna® (nilotinib) has been approved in the US as a new anti-cancer therapy for certain patients with a life-threatening form of leukemia who are resistant or intolerant to prior treatment including Glivec® (imatinib)*, an established treatment standard and a leading Novartis medicine. (worldpharmanews.com)

tumors with these mutations may respond to higher doses of imatinib. (arupconsult.com)

Imatinib approved by the US FDA (Food and Drug Administration) in 2001 was the mainstay of first-line drug for CML patients as the first-generation TKIs. (jcancer.org)
Mutational assessment is important because of the availability of specific, molecular-targeted therapy with KIT / PDGFRA tyrosine kinase inhibitors (TKIs) (eg, imatinib, sunitinib). (arupconsult.com)
Tyrosine kinase inhibitors (TKIs) are the drugs of choice for initial therapy of CML. (medscape.com)
Subsequently, second- and third-generation of TKIs (eg, dasatinib, nilotinib) were approved for first-line therapy. (medscape.com)
The second-generation TKIs have shown superior efficacy and higher rates of CCyR and MMR when compared with imatinib. (medscape.com)
In patients who receive first-line therapy with TKIs, the rate of decline in BCR-ABL1 transcripts correlates with long-term response. (medscape.com)
second-generation TKIs have shown greater efficacy and response compared to imatinib. (medscape.com)

Imatinib resistance, either primary or secondary, is associated with specific tumor genotypes, so genotyping of individual patient tumors helps guide decisions concerning whether to offer imatinib and at what dose, or whether an alternative tyrosine kinase inhibitor (TKI) (ie, sunitinib) is more appropriate. (arupconsult.com)
A study of DCC-2618 vs sunitinib in advanced GIST patients after treatment with imatinib (intrigue). (medscape.org)
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib: an international, multicenter, prospective, randomized, placebo-controlled phase 3 trial. (medscape.org)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomized controlled trial. (medscape.org)
Cytogenetic and molecular genetic findings were integrated and correlated with clinico-pathological parameters, including imatinib/sunitinib therapy response. (biomedcentral.com)
Originally called SU11248, sunitinib is an oral therapy belonging to a new class of multikinase inhibitors that attack cancer by inhibiting both tumor growth and blood supply. (cancernetwork.com)
At the recent American Society of Clinical Oncology (ASCO) 2006 Gastrointestinal Cancers Symposium in San Francisco, researchers from Dana-Farber Cancer Institute in Boston reported on a phase III clinical trial in which sunitinib was given to control GIST in patients whose tumors had become resistant to imatinib. (cancernetwork.com)
In addition to confirming the safety and efficacy of sunitinib, the findings illustrated that therapies targeting several signaling pathways inside cancer cells may be an effective treatment approach that may also be applicable to other difficult-to-treat cancers, including kidney cancer. (cancernetwork.com)
Sunitinib is the first molecularly targeted therapy proven to work against a cancer after another targeted therapy has failed," said the study's principal investigator, George Demetri, md, director of the Center for Sarcoma and Bone Oncology at Dana-Farber and associate professor of medicine at Harvard Medical School. (cancernetwork.com)
In the study, the research team led by Dr. Demetri compared overall survival and duration of tumor control in two groups of imatinib-resistant GIST patients-207 received sunitinib, and 105 received a placebo. (cancernetwork.com)
The benefits of sunitinib held steady regardless of the dose or duration of imatinib therapy that patients previously had received. (cancernetwork.com)
Aberrant platelet-derived growth factor receptor beta (PDGFRβ) signaling in cancer has motivated the development of several antagonists currently in clinical use, including imatinib, sunitinib, and sorafenib. (lu.se)

Imatinib is used to treat chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. (wikipedia.org)
On 1 February 2012, imatinib was approved for use after the surgical removal of KIT-positive tumors to help prevent recurrence. (wikipedia.org)
What is the role of mutational analysis in determining therapy for gastrointestinal stromal tumors? (arupconsult.com)
Bauer S, Joensuu H. Emerging agents for the treatment of advanced, imatinib-resistant gastrointestinal stromal tumors: current status and future directions. (medscape.org)
Ten-year progression-free and overall survival in patients with unresectable or metastatic GI stromal tumors: long-term analysis of the European Organization for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group intergroup phase III randomized trial on imatinib at two dose levels. (medscape.org)
Whereas oncogenic KIT or PDGFRA mutations seem vital to promote the neoplastic transformation, additional somatic alterations are presumably necessary for the biological and clinical progression of these tumors and may explain the different responses to targeted therapy seen in these patients. (biomedcentral.com)
Imatinib failed to activate EGF receptor signals in other tumor types, suggesting that COX-2 induction in imatinib-treated cells is mediated through release of autocrine factors expressed or activated in squamous tumors. (oldcitypublishing.com)
COX-2 induction by imatinib in squamous tumors derived from the head and neck region is unique with respect to other target-specific agents and may represent one of the unintended toxic effects of imatinib described in some patients. (oldcitypublishing.com)
The NCCN panel also included imatinib as a treatment for KIT-mutated tumors and pegylated interferon alfa-2b as an option for adjuvant therapy. (jnccn.org)
Here, in Part I, we describe areas where major inroads were initially achieved by targeting angiogenesis (central to the biology of renal cell carcinoma and hepatocellular cancer) and by unraveling pathways in the heterogeneous tumors of mesenchymal origin-spurred by the identification of c-Kit-activating mutations in gastrointestinal stromal tumors (GIST) and the regressions that ensued when tumors harboring these mutations were exposed to the tyrosine kinase inhibitor imatinib (Gleevec). (cancernetwork.com)
The situation with solid tumors is considerably more complex, and the evolution of targeted therapies for these cancers is still in its infancy. (cancernetwork.com)
Objectives: This study aimed to evaluate the stability, safety, and efficacy of alpha-targeted therapy with [225Ac]Ac-DOTATATE in patients with grade 1/2 metastatic neuroendocrine tumors (NETs). (bvsalud.org)

Dasatinib (Sprycel): Indicated for the treatment of adult patients with chronic myeloid leukemia in chronic, accelerated, or myeloid or lymphoid blast phase who are resistant or intolerant to prior therapy including imatinib. (medscape.com)
In this pivotal Phase III study, we confirmed that dasatinib gets more patients to high-quality remission faster than imatinib, making it a superior front-line therapy. (mdanderson.org)
For the multinational Phase III study, known as DASSIN (Dasatinib versus Imatinib Study In treatment-naïve CML patients), 519 newly diagnosed CML patients who had received no prior treatment were randomized to receive either dasatinib, also known as Sprycel ®, 100 milligrams once daily (259 patients), or imatinib, 400 milligrams once daily (260 patients). (mdanderson.org)
After a minimum follow-up of 12 months, the researchers found that the rates of confirmed CCyR and MMR in those taking dasatinib were 77 percent and 46 percent, respectively, compared to 66 percent and 28 percent, on the imatinib arm. (mdanderson.org)
In the DASISION (DASatinib versus Imatinib Study In treatment-Naive CML patients) trial, final 5-year analysis showed significantly higher MMR and molecular response with ≥4.5 log reduction of BCR-ABL on the International Scale (MR4.5) in patients with newly diagnosed CP-CML who received dasatinib, 100 mg once daily (n = 259), than in those who received imatinib, 400 mg once daily (n = 260). (medscape.com)
The DASISION study (DASatinib versus Imatinib Study In treatment-Naive CML patients) showed similar results: achieving major CyR by 3 or 6 months was a better predictor of PFS after initial treatment with first-line dasatinib in chronic-phase CML. (medscape.com)

Imatinib works by stopping the Bcr-Abl tyrosine-kinase. (wikipedia.org)
For treatment of progressive plexiform neurofibromas associated with neurofibromatosis type I, early research has shown potential for using the c-KIT tyrosine kinase blocking properties of imatinib. (wikipedia.org)
JOA displayed the activity of inhibiting the BCR-ABL and promoted differentiation of not only imatinib -sensitive but also imatinib -resistant cells with BCR-ABL mutation, which could become a potent lead compound to overcome the imatinib -resistant induced by inhibitors of BCR-ABL tyrosine kinase in CML therapy. (jcancer.org)
BCR-ABL oncogene encodes a BCR-ABL tyrosine kinase (TK), which triggers different downstream targets including c-Myc, STAT5 and CrkL, which participated in the control of cell differentiation, proliferation, migration and other cellular behaviors [ 3 - 5 ]. (jcancer.org)
Therefore, imatinib was a paradigm of targeted therapies, which due to that imatinib inhibits the phosphorylation of BCR-ABL then suppress the activation of BCR-ABL tyrosine kinase [ 6 ]. (jcancer.org)
To estimate the total value of survival gains associated with first- and second-line TKI therapy in chronic myeloid leukemia (CML) and the fraction of tyrosine kinase inhibitor (TKI)- related survival-gain value retained by patients and drug companies. (ajmc.com)
This research relates to the use of BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL), as little is known about the long-term and late effects of these therapies in young people. (stanford.edu)
Veenat 400mg containing the active ingredient imatinib is considered a protein tyrosine kinase inhibitor type of anticancer medication. (medypharma.com)
Imatinib (Veenat) is a tyrosine kinase inhibitor. (medypharma.com)

The development of targeted therapies has also been followed by resistance, reminiscent of an evolutionary arms race, as exemplified by imatinib and other BCR-ABL inhibitors for the treatment of chronic myelogenous leukaemia. (nature.com)
QINLOCK is a kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. (nih.gov)
Meanwhile, recent basic and clinical evidence have revealed another aspect of KIT-targeted therapy, namely the enhancement of antitumor activity of immune checkpoint inhibitors. (elsevierpure.com)

Due in part to the development of imatinib and related drugs, the five-year survival rate for people with chronic myeloid leukemia increased from 31% in 1993, to 59% in 2009, to 70% in 2016. (wikipedia.org)

In addition, this generic is indicated for the treatment of pediatric patients with newly diagnosed Ph+ CML in the chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib and newly diagnosed Ph+ ALL in combination with chemotherapy. (medscape.com)
Chronic and accelerated phase Ph+ CML in adults resistant or intolerant to prior therapy including imatinib. (empr.com)
Bristol-Myers Squibb Co. reported positive results from an ongoing phase 2 trial evaluating Sprycel in patients aged 18 years or younger with newly diagnosed chronic myeloid leukemia or Philadelphia chromosome-positive leukemias resistant to or intolerant of imatinib. (spglobal.com)
Patients resistant to or intolerant of imatinib who received Sprycel demonstrated a cumulative major cytogenetic response rate of 55.2% three months into treatment, exceeding the defined threshold of clinical interest of more than 30% for the primary endpoint of the cohort and increasing over time to greater than 90% at 24 months. (spglobal.com)
The secondary endpoint of estimated progression-free survival at 48 months was greater than 75% for patients resistant to or intolerant of imatinib and greater than 90% for patients newly diagnosed with the disease. (spglobal.com)
Sprycel was approved by the U.S. Food and Drug Administration in 2006 for adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to prior therapy including imatinib. (spglobal.com)
It is also an FDA-approved treatment in adult patients with Philadelphia chromosome-positive lymphoblastic leukemia who are resistant or intolerant to prior therapy. (spglobal.com)

A series of 80 patients diagnosed with GIST and submitted to surgery with curative intent were included in this study. (biomedcentral.com)
Although GIST is relatively uncommon, our understanding of it at the molecular level-down to specific mutations in DNA-has made this disease a proving ground for new therapies that could be useful for treating other cancers. (cancernetwork.com)

The IMPRES trial, a previous Phase 3 trial, demonstrated that oral imatinib may produce a markedly greater, and much more durable, treatment effect on exercise tolerance, than any other available PAH treatment, alone or in combination, based on the results observed in those patients who were maintained on the full imatinib dose for the majority of the trial. (biospace.com)

Imatinib is a small molecule inhibitor targeting multiple tyrosine kinases such as CSF1R, ABL, c-KIT, FLT3, and PDGFR-β. (wikipedia.org)

In the ENESTnd trial, which compared nilotinib with imatinib in patients with newly diagnosed CP-CML, by 5 years, more than half of all patients in the nilotinib arm achieved an MR(4.5) compared with less than a third of patients in the imatinib arm. (medscape.com)

Pazopanib is a multi-kinase inhibitor active against vascular endothelial growth factor receptors-1, -2 and -3 that is used in the therapy of advanced renal cell carcinoma and soft tissue sarcomas. (nih.gov)

After an initial regression of the disease, a second course of therapy was given at a reduced dose due to the toxicity of the treatment, with an associated lesser therapeutic effect. (nature.com)

Imatinib is considered to be a very effective treatment for CML, and has been shown to improve outcomes for people with this type of leukemia. (wikipedia.org)
It's important to note that while Imatinib is a very effective treatment for CML and some types of ALL, it is not a cure for leukemia. (wikipedia.org)
Some patients may need to continue taking Imatinib for an extended period of time to maintain remission, and some patients may eventually require additional treatment options. (wikipedia.org)
The U.S. Food and Drug Administration (FDA) has approved imatinib as first-line treatment for Philadelphia chromosome-positive CML, both in adults and children. (wikipedia.org)
In addition, the novel cancer stem cell paradigm raises the prospect of cell-targeted therapies instead of treatment directed against the whole tumour. (nature.com)
A new cell therapy will be available in Europe soon for the treatment of certain blood cancers. (medscape.com)
This chimeric antigen receptor (CAR) T-cell therapy is indicated for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), and follicular lymphoma grade 3B (FL3B). (medscape.com)
This generic is indicated for the treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy and pediatric patients with newly diagnosed Ph+ ALL in combination with chemotherapy. (medscape.com)
Over 20% of patients taking Nirmatrelvir-ritonavir therapy, commonly known as Paxlovid, suffer from the rebound, compared to less than the 2% chance seen in other treatment groups, a Harvard Medical School study revealed. (medicaldaily.com)
The Chronic Myeloid Leukemia market report provides current treatment practices, emerging drugs, Chronic Myeloid Leukemia market share of the individual therapies, current and forecasted Chronic Myeloid Leukemia market Size from 2019 to 2032 segmented by seven major markets. (delveinsight.com)
The DelveInsight's Chronic Myeloid Leukemia market report gives a thorough understanding of Chronic Myeloid Leukemia by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. (delveinsight.com)
The current treatment for incomplete hematopoietic recovery includes administration of factors stimulating white and red blood cell growth, such as granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF) and erythropoietin. (drugdiscoverynews.com)
Several groups are conducting trials to determine whether cellular therapy could be the treatment of choice for poor graft function after HSCT. (drugdiscoverynews.com)
Other groups are also working on cell therapies for the treatment of poor graft function after HSCT. (drugdiscoverynews.com)
As a result of a comprehensive review of cancer medicines recommended at the nineteenth meeting of the Expert Committee in 2013, the Committee recommended the addition of 16 new medicines for the treatment of specific cancers, including monoclonal antibodies (trastuzumab and rituximab) and targeted therapies (imatinib). (who.int)
The Committee recommended the addition to the WHO Model List of Essential Medicines of various direct-acting antiviral medicines, including fixed-dose combinations for the treatment of chronic hepatitis C, based on evidence supporting their substantial therapeutic benefit, satisfactory safety profile, and shorter treatment duration. (who.int)
These new medicines are included in WHO treatment programmes and are supported by WHO guidelines. (who.int)
Secondary KIT mutations were additionally found in two of four samples obtained after imatinib treatment. (biomedcentral.com)
Analysts have suggested it could achieve sales of around $500 million a year, potentially becoming a blockbuster product if its indications are expanded to include first-line treatment of leukaemia or other cancer indications. (pharmatimes.com)
His treatment course to date has included surgery, adjuvant radiotherapy, and interferon, metastasectomies, granulocyte-macrophage colony-stimulating factors, a clinical trial with the BRAF inhibitor vemurafenib (PLX-4032), clinical trial with combination BRAF plus MEK inhibition with vemurafenib plus GDC-0973, and combination targeted and immune therapy with vemurafenib plus the anti-CTLA4 antibody ipilimumab. (jnccn.org)
This case report illustrates the long-term management of a patient with metastatic melanoma using targeted and immune therapy, evolution in treatment guidelines, next directions in research, and the critical role of clinical trials in advancement of patient care. (jnccn.org)
FDA priority review status is granted to therapies that offer major advances in treatment or provide a treatment where no adequate therapy exists. (salesandmarketingnetwork.com)
Contact a doctor for the correct dosage and length of treatment as it will depend on the patients condition and their response to the therapy. (medypharma.com)
Dasatanib, a medication currently approved as treatment for drug-resistant chronic myeloid leukemia (CML), provided patients with quicker, better responses as a first therapy than the existing front-line drug, according to researchers at The University of Texas MD Anderson Cancer Center. (mdanderson.org)
Therefore, the knowledge of these possible interactions is fundamental for the implementation of a nutritional treatment in the presence of a pharmacological therapy. (mdpi.com)
This is the case of chronic kidney disease (CKD), for which the medication burden could be a problem, and nutritional therapy plays an important role in the patient's treatment. (mdpi.com)
[ 1 ] Imatinib was the first oral TKI approved for treatment of CML, in May 2001. (medscape.com)
Totally, a target size of 22 patients will be expected.Discussion:If this study shows efficacy and acceptable safety profile, it will contribute to the development of novel treatment option for patients with KIT-mutant melanoma that are refractory to standard therapy.Trial registration:NCT04546074. (elsevierpure.com)
For patients with advanced-stage metastatic castration-resistant prostate cancer (mCRPC) who do not respond to [177Lu]Lu-PSMA therapy, there are limited treatment options. (bvsalud.org)
Treatment should be planned according to clinical signs and symptoms and can vary from simple curettage associated with conservative therapies to en-bloc resection 25 . (bvsalud.org)

A precision therapy against cancer driven by KIT/PDGFRA mutations. (medscape.org)

In many cases, Imatinib can induce a complete cytogenetic response (CCyR) and major molecular response (MMR) and many patients can have a long-term remission. (wikipedia.org)
In the IRIS (International Randomized Study of Interferon and STI571) study, imatinib produced a higher rate of complete cytogenetic response (CCyR) and major cytogenetic response (MCyR) compared with interferon alpha and cytarabinenal. (medscape.com)
Early cytogenetic response or molecular response to second-line and subsequent TKI therapy have also been found to be good predictors of OS and PFS. (medscape.com)

COX-2 induction by imatinib was initiated through epidermal growth factor (EGF) receptor kinase activation and downstream signaling through mitogenic-activated protein kinase. (oldcitypublishing.com)

Here, we determined the effect of Jiyuan oridonin A (JOA), an ent -kaurene diterpenoid compound, on the differentiation blockade in imatinib-sensitive, particularly, imatinib-resistant CML cells with BCR-ABL-T315I mutation by cell proliferation assay, apoptosis analysis, cell differentiation analysis, cell cycle analysis and colony formation assay. (jcancer.org)

and Ph+ ALL and lymphoid blast CML with resistance or intolerance to prior therapy. (medscape.com)
3 Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. (hipaaspace.com)

T315I mutated BCR-ABL is the main cause of the resistance mediated by imatinib and second generation BCR-ABL inhibitor. (jcancer.org)
However, resistance to imatinib occurs in about 20 - 30% of patients with newly diagnosed CML in chronic phase [ 7 ]. (jcancer.org)

Cocco E, Scaltriti M, Drillon A. NTRK fusion-positive cancers and TRK inhibitor therapy. (medscape.org)
For each cancer discussed in the first part of our overview, as well as in Part II, which will deal with more common cancers, we briefly cover the tumor biology, how targeting was achieved, the introduction of immune modulation or immune-conjugates, and the impact these therapies are having in the disease. (cancernetwork.com)
In fact, we shall focus on integrating emerging treatments with therapeutic strategies that include both the older endocrine therapies (the "original targeted therapies") against breast and prostate cancers, and the empirically-derived successful chemotherapies, such as platinums, that are used in gynecologic cancers. (cancernetwork.com)
Bone cancers in children and teenagers include osteosarcoma and Ewing sarcoma. (cuanschutz.edu)
Intratumoral heterogeneity is an inherent feature of most human cancers and has profound implications for cancer therapy. (lu.se)
When people said, 'Targeted therapy is going to work for all advanced cancers,' they forgot that simple precept: You have to start earlier. (medscape.com)

Chemotherapy literally means therapy with chemicals. (leukaemia.org.nz)
First-line therapy in ES-SCLC currently consists of chemotherapy, combining a platinum drug with either etoposide or irinotecan as a possible alternative. (ersjournals.com)

One of the major chemotherapeutic advances over the past decade has been the discovery and deployment of targeted therapies directed at cancer-specific molecules and signaling pathways. (ajmc.com)
Imatinib did not activate stressor cytokine-signaling pathways (p38 kinase, nuclear factor-kB nuclear translocation) or affect COX-1 expression. (oldcitypublishing.com)
Imatinib acts on underlying cellular proliferative pathways associated with PAH and has the potential to be the first disease modifying therapy for PAH. (biospace.com)

However, 30-40 percent of imatinib patients do not achieve confirmed cytogenic complete response (CCyR), or the absence of the defective chromosome that causes the disease, within a year. (mdanderson.org)
Secondary endpoints included rate of and times to CCyR and major molecular response (MMR), defined as a level of .1 percent or lower of the defective chromosome, as well as safety. (mdanderson.org)

In 2006 the FDA expanded approved use to include dermatofibrosarcoma protuberans (DFSP), myelodysplastic/myeloproliferative diseases (MDS/MPD), and aggressive systemic mastocytosis (ASM). (wikipedia.org)
Nexavar, an oral anti-cancer drug, is the first and only approved systemic drug therapy for liver cancer and the only drug therapy shown to significantly improve overall survival in patients with the disease. (worldpharmanews.com)

Current therapeutic strategies for GISTs revolve around targeted therapy against PDGFRA , KIT , and related receptor tyrosine kinases. (arupconsult.com)
Its clinical activity and minimal toxicity are related to specific inhibition of cellular targets including BCR-ABL, platelet-derived growth factor receptor and c-kit kinases, resulting in the collapse of downstream signaling cascades important for transformation. (oldcitypublishing.com)
COX-2 induction by imatinib was blocked by MEK1 or EGF receptor inhibition. (oldcitypublishing.com)

Patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in the chronic phase (CP) after failure of interferon-alpha therapy. (hikma.com)
The three phases of Chronic Myeloid Leukemia includes Chronic phase Chronic Myeloid Leukemia, Accelerated phase Chronic Myeloid Leukemia, and Blast phase Chronic Myeloid Leukemia. (delveinsight.com)

Subsequent improved understanding of the molecular alterations present in the cancer cell has enabled the development of targeted therapies for some forms of cancer. (nature.com)
Pazopanib received approval for use in the United States in 2012 and current indications include advanced renal cell cancer and soft tissue sarcomas. (nih.gov)
We hoped that insights into the molecular biology of cancer would help identify potential vulnerabilities in cancer cells which we could then attack with specifically-designed targeted therapies. (leukaemia.org.au)
The National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO) consider mutational analysis standard practice and strongly encourage including it in the diagnostic workup for all GISTS. (arupconsult.com)
The cancer medicines section of both Model Lists was updated to include specific indications for which each medicine was recommended. (who.int)
1 Improvements in survival have been particularly dramatic for breast cancer, colon cancer, and non-Hodgkin lymphoma-conditions for which there have been important advances in therapy, screening, or both. (ajmc.com)
2-4 It has, however, also been argued that some new cancer therapies only marginally extend life, and at a high cost. (ajmc.com)
The Department of Imaging provides dedicated cancer imaging services, including consultation services and cancer therapy with radioactive unsealed sources. (dana-farber.org)
I am passionate about the intersection between clinical care and clinical research, and committed to understanding the long-term effects of childhood cancer therapies over the course of our patients' lifetimes. (stanford.edu)
The CU Cancer Center has a multidisciplinary program for sarcomas , including bone cancer. (cuanschutz.edu)
There are numerous clinical trials being conducted by CU Cancer Center members at any time, including trials that enroll bone sarcomas. (cuanschutz.edu)
These include surgery, which can cure the disease in some cases, and targeted therapies, which can help reduce-or delay-the recurrence of the cancer. (yalemedicine.org)
Imatinib cancer medication blocks the activity of this enzyme, which delivers a signal that causes cells to multiply. (medypharma.com)
We've learned that in cancer therapy, it's important to use your big guns up front. (mdanderson.org)
The International Association for the Study of Lung Cancer defines limited-stage SCLC (LS-SCLC) as: "disease restricted to one hemithorax with regional lymph node metastases, including hilar, ipsilateral and contralateral mediastinal, and ipsilateral and contralateral supraclavicular nodes and should also include patients with ipsilateral pleural effusion independent of whether cytology is positive or negative" 2 . (ersjournals.com)
It is also used with surgery and radioactive iodine therapy to treat thyroid cancer. (medlineplus.gov)
Overview of Cancer Therapy Curing cancer requires eliminating all cells capable of causing cancer recurrence in a person's lifetime. (msdmanuals.com)
The number of approved cancer therapies is increasing rapidly. (msdmanuals.com)
To everybody's surprise, including me, he got up and said, "Penny, my wife, and I will donate $500 million for cancer research if you raise a matching amount in 2 years, and it's all or nothing. (medscape.com)
The view of the community was that single-agent therapy for cancer will never work. (medscape.com)

Fraticelli P, Kafyeke A, Mattioli M, Martino GP, Murri M, Gabrielli A. Idiopathic hypereosinophilic syndrome presenting with severe vasculitis successfully treated with imatinib. (wjgnet.com)
Pazopanib therapy is commonly associated with transient elevations in serum aminotransferase during therapy and has been linked to rare, but occasionally severe and even fatal cases of clinically apparent acute liver injury. (nih.gov)
Severe hepatotoxicity including fatalities can occur. (medypharma.com)

We found that JOA at lower concentration significantly inhibited the proliferation of CML cells expressing mutant BCR-ABL (T315I mutation included) and wild-type BCR-ABL, which was due to that JOA induced the cell differentiation and the cell cycle arrest at G0/G1 phase. (jcancer.org)
His tumor tissue was sent to Foundation Medicine for testing, which revealed a high number of pathogenic genomic alterations, including a mutation in PTCH1 . (jnccn.org)

The secondary endpoints include progression free survival, overall survival, best overall response and incidence of adverse events. (elsevierpure.com)

This study compared current reporting within the Durban Metropolitan complex with the MST METHODS: This observational retrospective study included 130 upper gastrointestinal endoscopy reports from five different hospitals. (scielo.org.za)
A phase II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GSIT). (medscape.org)

In some patients, unexpected toxicities arise that are not associated with inhibition of any known cellular imatinib target. (oldcitypublishing.com)

Chronic Myeloid Leukemia signs and symptoms tend to develop gradually which includes Weakness, Fatigue, Shortness of breath during basic everyday activities, Unexplained weight loss etc. (delveinsight.com)
Signs and symptoms of chronic myelogenous leukemia include weight loss and tiredness. (hartfordhealthcare.org)

Other options for CML during pregnancy include termination of pregnancy, close monitoring or interferon-alfa. (cancerinpregnancy.org)

One hundred and thirty patients were included in the study, of which 60 were female. (scielo.org.za)
Several medications and therapies are in the very early phases of study for scleroderma. (mountsinai.org)
The study included 667 patients from Massachusetts with 5116 patients in 8 other states (representing the control states) before and after the copay ban was lifted. (ahdbonline.com)
A study by Tang et al determined that long-term TKI therapy may reduce the abundance of leukemic stem cells in select patients. (medscape.com)
[ 4 ] A study by Gugliotta et al that examined the use of imatinib in patients aged 65 years or older found that the response to imatinib was not affected by age. (medscape.com)

Imatinib should be used with caution during pregnancy, balancing the risk to the fetus versus the risk to the mother. (cancerinpregnancy.org)

Yet there are several key needs that still need to be met for people with ALL, including better treatments for the 10-20% of children with ALL who relapse , developing treatments with less side effects , better treatments for older adults , and new therapies for T-ALL . (leukaemia.org.au)

Anatomy14

Organisms3

Diseases42

Chemicals and Drugs57

Analytical, Diagnostic and Therapeutic Techniques and Equipment48

Phenomena and Processes29

Disciplines and Occupations2

Anthropology, Education, Sociology and Social Phenomena2

Information Science1

Health Care16

Mesylate20

Gleevec8

Glivec5

Higher doses of imatinib1

TKIs7

Sunitinib12

Tumors12

Dasatinib6

Tyrosine kinase9

Inhibitors3

Development of imatinib1

Intolerant7

GIST2

Oral imatinib1

Small molecule inhibitor1

Nilotinib1

Kinase inhibitor1

Regression of the disease1

Treatment30

Mutations1

Cytogenetic response3

Protein kinase1

Resistant1

Intolerance2

Resistance2

Cancers6

Chemotherapy2

Pathways3

CCyR2

Systemic2

Receptor3

Chronic phase2

Cancer20

Severe3

Mutation2

Progression1

Gastrointestinal2

Cellular1

Symptoms2

Interferon1

Study5

Versus1

Treatments1